Akers Biosciences Inc (LSE:AKR) - Share price - Overview

Stock Report

Akers Biosciences Inc AKR

Last Price
GBX155.00

Day Change
37.50|31.91%

As of 28/03/2017
18:14:33 BST | GBX
Minimum 15 Minutes Delay.

Last Close117.50p
Day Range110.00 - 165.00
Mkt Cap8.51Mil
52-Wk Range86.00 - 255.00
Yield %0.00
ISINUS00973E1029
Volume47,962
P/E-1.34
P/S5.58
P/CF-2.30

Share Price

Total Returns 28/03/2017

 Chg (%)  
More ...
Akers Biosciences Inc47.62 
FTSE 100 TR GBP0.79
 
Financials
201320142015
More ...
Income Statement
Turnover2.302.691.43
Operating Profit-1.16-1.95-6.54
Net Profit-0.98-1.90-6.29
Reported EPS-61.67-40.16-122.17
Balance Sheet
Current Assets2.048.394.37
Non Current Assets1.642.311.21
Total Assets3.6810.705.58
Current Liabilities1.001.191.13
Total Liabilities1.181.191.13
Total Equity2.509.514.46
Cash Flow
Operating Cash Flow-1.75-2.37-3.47
Net Change in Cash-0.340.21-0.04
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
--------
--------

Company Profile

Akers Biosciences Inc is engaged in the development and sale of disposable diagnostic testing device. The Company develops, manufactures, and supplies rapid, point-of-care screening and testing products.

Sector

Medical Instruments & Supplies

Market Position

1549 of 1851 Companies

Index

Outlook

(01/02/2017) "...total product revenue for the twelve months ended 31 December 2016 is expected to be approximately $3.00m, representing an increase of 66.0% over the prior year's product revenue of $1.80m"

Next Event 28/03/2017

Next prelim announcement
Ratios
CompSecMkt
More ...
PER (E)0.0018.4716.20
Div Yld (E)0.001.764.14
PEG (E)0.000.571.00
ROCE-177.6531.94121.43
Op Mrgn-435.92-4.81-8.93
EPS Grwth0.0038.4835.80
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanTom Knox
Chief Scientific Dir, CEO, President & CDr. Raymond Akers
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.